Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Publicity associated with recent reports of a greater frequency of adenocarcinoma of the endometrium among women who take exogenous estrogens has created confusion among physicians and fear among patients. An objective review of available data on estrogen effects and current epidemiologic evidence suggests that estrogen may play an indirect role in the development of endometrial carcinoma. Until definitive data are available, physicians should exercise caution in prescribing estrogens, monitoring the status of the endometrium at regular intervals by sampling and pathologic analysis.
AJR Am J Roentgenol 1976 Dec
PMID:ARS Presidential Address: Estrogen therapy: a causal role in endometrial cancer? 99 25

An analysis is made of 3 reports of American studies which linked the postmenopausal use of estrogens to endometrial cancer. In regard to the accuracy of these studies, the author emphasizes that proper attention must be paid 1st to the state of those subjects in the control group and, more importantly, to the presence of other risk factors in the patients. Most disorders and diseases in which estrogens are employed as therapy are also noted to be risk factors in the diagnosis of endometrial carcinoma. These include adiposity, diabetes, high blood pressure, infertility, prolonged cyclical disruptions, menopause, and the social status of the patient (in which the increased use of estrogens and other possible carcinogens is noted to exceed that of poorer class patients). The possible dangers of the use of estrogens are recognized, however, and must certainly be particularly considered when the patient shows 1 or more other risk factors. A guideline for postmenopausal administration of estrogens is given.
Fortschr Med 1976 Dec 02
PMID:[Estrogens and carcinoma of the endometrium]. 100 92

The course of development of the human genital tract is undifferentiated up to the 9th week (32 mm). At this time both Wolffian (mesonephric) and Mullerian (paramesonephric) ducts are present as symmetric paired structures. These, together with the urogenital sinus and the metanephric ducts, provide the tissue sources for the internal genital and urinary apparatus, exclusive of the gonads and kidneys. Configuration of the oviducts varies among species. Most human anomalies may be represented in other species so that some authors consider them to be atavistic reversions. The gonad of the developing male fetus plays a critical role in the formation of the genital tract. It elaborates androgenic steroids and a polypeptide, a Mullerian inhibiting substance, which induced suppression and resorotion of the Mullerian ducts. In the female the Mullerian ducts grow and develop into their adult morphology while the Wolffian ducts persist only as microscopic islands. The development of the external genitals and secondary sex characteristics depends upon further exposure to androgenic or estrogenic hormone milieu. a case is reported of an instance of congenital absence of the upper vagina. At laparotomy normal sized uterus, tubes, and ovaries were found. Further plastic surgery via the vagina corrected the condition. 15 years later (age 32) it was learned that she had been married and had 3 pregnancies. The adenosis, areas of squamous metaplasia, and deformities of the cervix of girls exposed in utero to diethylestibestrol are examples of deranged development. The shallow depth or absence of the vaginal canal of individuals with testicular feminization are also due to faulty development. Both Mullerian tissue and that of the urogenital sinus origin normally participate in the development of the vagina. In the normal adult the squamous cells that line the vagina contain abundant glycogen indicating urogenital origin. Glycogen-deficient squamous cells and adenosis are thought to be of Mullerian origin. In an accompanying discussion additional details of development are mentioned. It was noted that 7 cases of adenocarcinoma of the prostatic utricle in males have been reported as resembling endometrial carcinoma. The prostatic utricle is a homologue of the uterus and upper vagina and may be involved in similar deranged developments
Am J Obstet Gynecol 1976 Dec 01
PMID:The embryologic development of the human vagina. 103 67

The histological and cytological assessment of material obtained with an intrauterine jet washing device from 138 patients with postmenopausal bleeding, abnormal premenopausal bleeding or infertility is presented. In the first part of the study 55 washings were examined by histological techniques and the findings compared with those in material subsequently obtained by curettage or endometrial biopsy. Only 32 (58 per cent) of the washings were satisfactory for evaluation of the endometrium compared with 46 (84 per cent) of the curettings. When, in the second part of the study the washings in 83 cases were examined by both histological and cytological methods, 76 (92 per cent) were satisfactory compared with 59 (71 per cent) of the curettings. Cytological examination of the washings in the postmenopausal women provided a significantly higher proportion of satisfactory specimens than histological examination alone or evaluation of the curettings. In the whole study, three cases of endometrial carcinoma were diagnosed by endometrial washings and by curettage, while in six cases of endometrial hyperplasia one false negative was obtained by histological examination of the washings and one by examination of the curettings. This study shows that endometrial samples obtained with the intrauterine jet washer provide information about the endometrium which is comparable with that obtained by conventional curettage, and also that in postmenopausal women endometrial lavage may be more reliable than curettage.
Br J Obstet Gynaecol 1975 Dec
PMID:Endometrial washings histological and cytological assessment of material obtained with an intrauterine jet washing device. 110 58

To determine the association between the incidence of endometrial cancer and the use of estrogen in menopausal and post-menopausal women, we retrospectively compared 317 patients with adenocarcinoma of the endometrium with an equal number of matched controls having other gynecologic neoplasms; 152 patients used estrogen, as compared to 54 of 317 controls. Thus, the risk of endometrial cancer was 4.5 times greater among women exposed to estrogen therapy. When estrogen use was adjusted for concomitant variables such as obesity, hypertension, diabetes, parity, referral pattern, age at diagnosis, year of diagnosis and other gynecologic neoplasms, the magnitude of the increased relative risk was associated with several of these variables, and was highest in patients without obesity and hypertension. Exogenous estrogen therapy is associated with an increased risk of endometrial carcinoma, but this increased relative risk is less apparent in patients with physiologic characteristics previously associated with an increased risk.
N Engl J Med 1975 Dec 04
PMID:Association of exogenous estrogen and endometrial carcinoma. 118 89

A cancer-inducing role for endogenous estrogens has been confounded by increased evidence of human female breast and endometrial cancer after the menopause when estrogen production is decreasing. The endocrine change occurring after the menopause is a shift from estradiol-17-Beta of ovarian origin to estrone synthesized in the periphery. Reports have indicated that a risk of endometrial cancer is considerably higher in menopausal women and up to 5 times higher in women taking estrogen. Thromboembolism, coronary disease and stroke are estrogen-related risks which appear age and dose-dependent. When the putative cancer risk is added to these risks, estrogens become agents which should be used with care. Risks such as prior thromboembolic events, migraine headaches, a family history of cancer or excessive smoking should be considered as contraindications to estrogen use. All these factors contribute to the need for more research and knowledge in the area of the altered hormonal state of the untreated menopause.
N Engl J Med 1975 Dec 04
PMID:Editorial: Cancer risk and estrogen use in the menopause. 118 92

Existing data indicate that high levels of endogenous estrogens, in particular estrone, predispose to endometrial cancer. Estrogen preparations came into use in the 1930s, and evidence has been accumulating to incriminate them also in cases of endometrial cancer. A recent rise in the incidence of endometrial cancer has followed wider use of these hormones. The risk among postmenopausal estrogen users has been estimated to be 4-8 times the 1/1000/year of postmenopausal nonusers. If estrogens are prescribed to menopausal and postmenopausal patients, such patients should be monitored for the development of endometrial carcinoma. Whether they should be given estrogens at all is still controversial.
N Engl J Med 1975 Dec 04
PMID:Editorial: Risks and benefits of estrogen use. 118 93

The withdrawal from the market of the oral contraceptives Volidan 21 and Serial 28 was based on work in beagle dogs treated for 7 years with high doses of megestrol acetate. The treated animals developed significantly more tumors than untreated controls. Chlormadinone acetate was withdrawn from clinical use in 1970 on the basis of similar reports. All other progestogens in use in Britain had no effect on the incidence of tumors. The only neoplasm linked with oral contraceptives by clinical evidence is hepatic adenoma. In menopausal and postmenopausal patients estrogen therapy may increase the risk of endometrial uterine cancer. For most young women oral contraception is a compromise between safety and reliability. Serious thromboembolic complications increase with age, cigarette smoking, and hypertension. Patients should be screened for the presence of risk factors and the effects of treatment regularly assessed. In menopausal women, regular monitoring for endometrial cancer is advised. Medical supervision of hormone therapy is needed.
Br Med J 1975 Dec 13
PMID:Editorial: Cancer risks from hormone treatment. 120 97

We have examined the effects of protein kinase-C (PKC) activation on expression of the six known insulin-like growth factor-binding proteins (IGFBPs) by human endometrial carcinoma cells. Each of six known IGFBPs was expressed in one or more of the three cell lines examined. The addition of 10(-7) M 4 beta-phorbol 12-myristate 13-acetate (PMA) to HEC-50 and HEC-1B cells resulted in changes in cell morphology, growth inhibition, activation of PKC, and an increase in expression of IGFBP-1. PMA had no effect on these parameters in the Ishikawa cell line, which did not express IGFBP-1. In HEC-50 cells, the effect of PMA was blocked by the concomitant addition of the PKC inhibitor staurosporin and the simultaneous addition of cycloheximide. PMA also resulted in an increase in IGFBP-3 in HEC-50 cells and an increase in IGFBP-6 expression in HEC-1B cells. In contrast, IGFBP-3 expression was down-regulated by PMA in HEC-1B and Ishikawa cells. The abundance of IGFBP-2 and IGFBP-5 mRNAs was also reduced in HEC-1B and Ishikawa cells, respectively. IGFBP-4 was expressed only in HEC-50 cells and was not affected by PMA treatment. These data establish a role for the PKC pathway in regulation of expression of IGFBP-1, -2, -3, and -5 in endometrial adenocarcinoma cells and illustrate the complexity of cell type-specific expression of the IGFBPs.
Endocrinology 1992 Dec
PMID:Phorbol esters differentially regulate the expression of insulin-like growth factor-binding proteins in endometrial carcinoma cells. 128 Feb 5

The authors present the histological evaluation of preparations collected during surgery during treatment of endometrial carcinoma in a clinical group of 199 women. Decision on subsequent therapeutic procedures depends on the bioptic risk of the score which comprises the type and grading of the tumour, angioinvasion and possible spread. Subsequent adjuvant therapy according to the above criteria was administered to 50% of the women. The classification grade, as compared with the preoperative stating, was raised in almost 40% of the women. The asset of evaluation of the risk score is establishment of a more accurate diagnosis and formulation of corresponding adjuvant therapy.
Cesk Gynekol 1992 Dec
PMID:[Present surgical approach to treatment of endometrial carcinoma]. 129 Nov 26


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>